Michael Hallek to Antibodies, Neoplasm
This is a "connection" page, showing publications Michael Hallek has written about Antibodies, Neoplasm.
Connection Strength
0.124
-
Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec; 49(12):2256-62.
Score: 0.098
-
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
Score: 0.026